KABI'S LINOMIDE IN PHASE III FOR AML
Kabi Pharmacia's immunomodulator compound Linomide (roquinimex) has now entered Phase III testing as a treatment for acute myeloid leukemia patients. The trial will be conducted at 25 centers across the USA, Canada and Australia.
Linomide will be compared to placebo for its efficacy in preventing relapse in AML patients. 105 subjects have been recruited so far, with the target being at least 300. The trial will take one year to complete in the first instance, and the major endpoint will be mortality rates. A pilot study in chronic myeloid leukemia is also ongoing.
According to the Pink Sheet, Linomide is also being investigated as a treatment for multiple sclerosis, both the relapsing-remitting and progressive forms of the disease. Two Phase II trials are planned to evaluate Linomide's efficacy in these patients. Around 30 patients will be included in each study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze